Summary
Cellular proliferation depends on the rates of both cell division and cell death. Tumors frequently have decreased cell death as a primary mode of increased cell proliferation. Genetic changes resulting in loss of programmed cell death (apoptosis) are likely to be critical components of tumorigenesis. Many of the gene products which appear to control apoptotic tendencies are regulators of cell cycle progression; thus, cell cycle control and cell death appear to be tightly linked processes. P53 protein is an example of a gene product which affects both cell cycle progression and apoptosis. The ability of p53 overexpression to induce apoptosis may be a major reason why tumor cells frequently disable p53 during the transformation process. Unfortunately, the same genetic changes which cause loss of apoptosis during tumordevelopment, may also result in tumor cellresistance to anti-neoplastic therapies which kill tumor cells by apoptosis. Elucidation of the genetic and biochemical controls of these cellular responses may provide insights into ways to induce cell death and thus hopefully suggest new targets for improving therapeutic index in the treatment of malignancies.
Similar content being viewed by others
References
Wyllie AH: Apoptosis (The 1992 Frank Rose Memorial Lecture). Br J Cancer 67: 205–208, 1993
Bakhshi A, Jensen JP, Goldman P, Wright JJ, Mcbride OW, Epstein AL, Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 14: 889–906, 1985
Sentman CL, Shutter JR, Hockenbery D, Knagawa O, Korsmeyer SJ: bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879–888, 1991
Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterdimerizesin vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 74: 609–619, 1993
Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597–608, 1993
Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW: Mcl-1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to Bcl-2. Proc Natl Acad Sci USA 90: 3516–3520, 1993
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345–347, 1991
Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T: p53-dependent apoptosis suppresses tumor growth and progressionin vivo. Cell 78: 703–711, 1994
Morgenbesser SD, Williams BO, Jacks T, DePinho RA: p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371: 72–74, 1994
Pan H, Griep AE: Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development. Genes & Development 8: 1285–1299, 1994
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Water CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119–128, 1992
Meikrantz W, Gisselbrecht S, Tam SW, Schlegel R: Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 91: 3754–3758, 1994
Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH: Premature p34cdc2 activation required for apoptosis. Science 263: 1143–1145, 1994
Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83: 2038–2044, 1994
McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG:BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179–1187, 1994
Milner AE, Grand RJA, Waters CM, Gregory CD: Apoptosis in Burkitt lymphoma cell is driven by c-myc. Oncogene 8: 3385–3391, 1993
Wyllie AH, Rose KA, Morris RG, Steel CM, Foster E, Spandidos DA: Rodent fibroblast tumours expressing humanmyc andras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 56: 251–259, 1987
Debbas M, White E: Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & Development 7: 546–554, 1993
Lowe SW, Ruley HE: Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes & Development 7: 535–545, 1993
White AE, Livanos EM, Tlsty TD: Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes & Dev 8: 666–677, 1994
Wu X, Levine AJ: p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91: 3602–3606, 1991
Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA: Effects of an Rb mutation in the mouse. Nature 359: 295–300, 1992
Clarke AR, Maandag ER, van Roon M, van der Lugt NMT, van der Valk M, Hooper ML, Berns A, te Riele H: Requirement for a functional Rb-1 gene in murine development. Nature 359: 328–330, 1992
Lee EYP, Chang C, Hu N, Wang YJ, Lai C, Herrup K, Lee W, Bradley A: Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359: 288–294, 1992
Lane DP, Crawford LV: T antigen is bound to host protein in SV40 transformed cells. Nature 278: 261–263, 1979
Linzer DI, Levine AJ: Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43–52, 1979
Deleo AB, Jay G, Appells E, Dubois GC, Law LW, Old LJ: Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 76: 2420–2424, 1979
Crawford L: The 53,000-dalton cellular protein and its role in transformation. Int Rev Exp Pathol 25: 1–50, 1983
Eliyahu D, Raz A, Gruss P, Givol D, Oren M: Participation of p53 cellular tumor antigen in transformation of normal embryonic cells. Nature (London) 312: 646–649, 1984
Hinds PW, Finlay CA, Levine AJ: Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63: 739–746, 1989
Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772–5781, 1990
Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912–915, 1990
Martinez J, Goergoff I, Levine AJ: Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5: 151–159, 1991
Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 muttions in human cancers. Science 253: 49–53, 1991
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705–708, 1989
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491–494, 1989
Harris CC: p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980–1981, 1993
Malkin D, Li FP, Strong LC, Fraumeni JF, Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FA, Tainsky MA, Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233–1238, 1990
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH: Germ-line transmission of a mutated p53 gene in a cancerprone family with Li-Fraumeni syndrome. Nature 348: 747–749, 1990
Fields S, Jang SK: Prsence of a potent transcription activating sequence in the p53 protein. Science 249: 1046–1049, 1990
Raycroft L, Wu HY, Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 antioncogene. Science 249: 1049–1051, 1990
Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C: Wild-type p53 activates transcriptionin vitro. Nature 358: 83–86, 1992
Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C: Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65: 1083–1091, 1991
Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B: Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708–1711, 1991
El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B: Definition of a consensus binding site for p53. Nature 356: 215–221, 1992
Funk WD, Pak DT, Karas RH, Wright WE, Shay JW: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 12: 2866–2871, 1992
Kern SE, Kinzler KW, Baker SJ, Nigro JM, Rotter V, Levine AJ, Friedman P, Prives C, Vogelstein B: Mutant p53 proteins bind DNA abnormallyin vitro. Oncogene 6: 131–136, 1991
Unger T, Nau MM, Segal S, Minna JD: p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11: 1383–1390, 1992
Cho Y, Gorina S, Jeffery PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346–355, 1994
Kern SE, Pietenpol JA, Thiagalingam S, Seymor A, Kinzler KW, Vogelstein B: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256: 827–830, 1992
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci 89: 7491–7495, 1992
Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nat Genet 4: 42–46, 1993
Michalovitz D, Halevy O, Oren M: p53 mutations: gains or losses? J Cell Biochem 45: 22–29, 1991
Barak Y, Oren M: Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO 11: 2115–2121, 1992
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein mdm2 conceals the activation domain of tumor suppressor p53. Nature 362: 857–860, 1993
Finlay CA: The mdm2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol 13: 301–306, 1993
Momand J, Zambetti GP, Olson DC, George DL, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245, 1992
Zauberman A, Barak Y, Ragimov N, Levy N, Oren M: Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO J 12: 2799–2808, 1993
Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53: 2736–2739, 1993
Leach FS, Tokins T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B: p53 mutation and mdm2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231–2234, 1993
Oliner JD, Kinzler KW, Meltzer P, George DL, Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83, 1992
Sheikh MS, Shao ZM, Hussain A, Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53: 3226–3228, 1993
Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453–456, 1991
Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70: 523–526, 1992
Doll R, Peto R: The causes of cancer in the United States today. J Natl Cancer Inst 66: 1192–1308, 1981
Busse PM, Bose SK, Jones RW, Tolmach LJ: The action of caffeine on X-irradiated HeLa cells. II. Synergistic lethality. Radiat Res 71: 666–677, 1977
Denekamp J: Cell kinetics and radiation biology. Int J Radiat Biol 49: 357–380, 1986
Weinert TA, Hartwell LH: The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241: 317–322, 1988
Little JB: Delayed initiation of DNA synthesis in irradiated human diploid cells. Nature 218: 1064–1065, 1968
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304–6311, 1991
Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ, Jr: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587–597, 1992
Hartwell LH, Weinert TA: Checkpoints: Controls that ensure the order of cell cycle events. Science 246: 629–634, 1989
Nelson WG, Kastan MB: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815–1823, 1994
Zhan Q, Bae I, Kastan MB, Fornace AJ, Jr: The p53-dependent gamma-Ray response of GADD45. Cancer Res 54: 2755–2760, 1994
Khanna KK, Lavin MF: Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8: 3307–3312, 1993
Price BD, Park SJ: DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells. Cancer Res 54: 896–899, 1994
Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper W, Elledge SJ, Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013–1023, 1994
Canman CE, Wolff AC, Chen C, Fornace AJ, Kastan MB: The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 54: 5054–5058, 1994
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 76: 817–825, 1993
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816, 1993
Xiong Y, Hannon GH, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701–704, 1993
Xiong Y, Zhang H, Beach D: Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7: 1572–1583, 1993
Noda A, Ning Y, Venable SF, Perreira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90–98, 1994
Slebos RJC, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, Cho KR: p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 91: 5320–5324, 1994
El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B: WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174, 1994
Lin BT, Gruenwald S, Morla AO, Lee WH, Wang JY: Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J 10: 857–864, 1991
Nevins JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424–429, 1992
Weintraub SJ, Prater CA, Dean DC: Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358: 259–261, 1992
Arroyo M, Raychaudhuri P: Retinoblastoma-repression of E2F-dependent transcription depends on the ability of the retinoblastoma protein to interact with E2F and is abrogated by the adenovirus E1A oncoprotein. Nucleic Acids Res 20: 5947–5954, 1992
Zhan Q, Carrier F, Fornace AJ, Jr: Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Molecular and cellular biology 13: 4242–4250, 1993
Zhan Q, Lord KA, Alamo I, Jr, Hollander MC, Carrier F, Ron D, Kohn KW, Hoffman B, Liebermann DA, Fornace AJ, Jr: Thegadd andMyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol 14: 2361–2371, 1994
Smith ML, Chen I, Bae I, Chen C, Gilmer T, Kastan MB, O'Connor PM, Fornace AJ: Physical and functional interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266: 1376–1380, 1994
Chen C, Oliner JD, Zhan Q, Fornace AJ, Jr, Vogelstein B, Kastan MB: Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 91: 2684–2688, 1994
Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ: The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 90: 11623–11627, 1993
Barak Y, Juven T, Haffner R, Oren M: mdm2 expression is induced by wild type p53 activity. EMBO 12: 461–468, 1993
Juven T, Barak Y, Zauberman A, George DL, Oren M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411–3416, 1993
Wu X, Bayle H, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes and Develop 7: 1126–1132, 1993
Otto A, Deppert W: A tumor cells tolerating wild-type p53. Oncogene 8: 2591–2603, 1993
Sellins KS, Cohen JJ: Gene induction by -irradiation leads to DNA fragmentation in lymphocytes. J Immunol 139: 3199–3206, 1987
Lowe SW, Schmitt SW, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847–849, 1993
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849–852, 1993
Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967, 1993
Lotem J, Sachs L: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82: 1092–1096, 1993
Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB: Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53: 4164–4168, 1993
Michalovitz D, Halevy O, Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671–680, 1990
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345–347, 1991
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215–221, 1992
Carder P, Wyllie AH, Purdie CA, Morris RG, White S, Piris J, Bird CC: Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8: 1397–1401, 1993
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923–935, 1992
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM: Wild-type p53 restores cell cycle and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937–948, 1992
Schaefer DI, Livano EM, White AE, Tlsty TD: Multiple mechanisms of n-(phosphonoacetyl)-1-aspartate drug resistance in SV40-infected precrisis human fibroblasts. Cancer Res 53: 4946–4951, 1993
Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ: Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci 90: 3221–3225, 1993
Reid BJ, Sanchez CA, Blount PA, Levine DS: Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105: 119–129, 1993
Lowe SW, Jacks T, Housman DE, Ruley HE: Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 91: 2026–2030, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kastan, M.B., Canman, C.E. & Leonard, C.J. P53, cell cycle control and apoptosis: Implications for cancer. Cancer Metast Rev 14, 3–15 (1995). https://doi.org/10.1007/BF00690207
Issue Date:
DOI: https://doi.org/10.1007/BF00690207